Notice for atezolizumab (Roche Products Pty Limited)
Active ingredients
atezolizumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
atezolizumab in combinatinon with bevacizumab, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Therapeutic area
Oncology